Aromatase Inhibitors 2006
DOI: 10.1007/3-7643-7418-7_1
|View full text |Cite
|
Sign up to set email alerts
|

Background and development of aromatase inhibitors

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
2
1

Citation Types

0
3
0

Year Published

2011
2011
2024
2024

Publication Types

Select...
4
2

Relationship

1
5

Authors

Journals

citations
Cited by 9 publications
(3 citation statements)
references
References 99 publications
0
3
0
Order By: Relevance
“…To produce the estrogen deficiency in male rats, we used letrozole -a third--generation inhibitor of aromatase. The letrozole structure provides a good fit with the substrate-binding site and additionally co-ordinates with aromatase heme iron and effectively inhibits the hydroxylationa reaction necessary for aromatization [25]. Because of the ability of letrozole to reduce serum estradiol concentration, it is usually used in the treatment of estrogen-sensitive breast cancer in women [26][27][28].…”
Section: Discussionmentioning
confidence: 99%
“…To produce the estrogen deficiency in male rats, we used letrozole -a third--generation inhibitor of aromatase. The letrozole structure provides a good fit with the substrate-binding site and additionally co-ordinates with aromatase heme iron and effectively inhibits the hydroxylationa reaction necessary for aromatization [25]. Because of the ability of letrozole to reduce serum estradiol concentration, it is usually used in the treatment of estrogen-sensitive breast cancer in women [26][27][28].…”
Section: Discussionmentioning
confidence: 99%
“…In terms of deprivation, trophic effects of oestrogen may be reduced by inhibiting biosynthesis or by blockade of hormone action [1,2]. In recent times the pharmaceutical industry has been extremely successful in developing agents such as aromatase inhibitors and anti-oestrogens [3][4][5] which efficiently and specifically affect these processes. Such drugs have advanced scientific knowledge and clinical practice in a variety of settings.…”
Section: Introductionmentioning
confidence: 99%
“…ten-fold PDE affinity (3.1 ng/mL; 6.6 nM) (Saenz De Tejada et al 2001 ). Morelloflavone was shown to inhibit phospholipase A2 at IC 50 = 0.9 µM (Gil et al 1997 ), aromatase at 3.1 µM (Recalde-Gil et al 2019 ), MAO-A at 5.1 µM (Recalde-Gil et al 2017 ), and HMG-CoA at 80.9 µM (Tuansulong et al 2011 ), which are again levels incomparable to commonly used drugs—darapladib (8.6 nM) (Hu et al 2015 ), anastrazole (Arimidex®; 15 nM) (Miller 2006 ), harmaline (2.3 nM) (Kilpatrick et al 2001 ), and mevastatin (23 nM) (Lin et al 2015 ). Since all G. kola biflavonoids are structurally related, similar affinities may be expected for all of them.…”
Section: Discussionmentioning
confidence: 99%